Mariam Khanfar

Mariam Khanfar

Auto-generated profile, based on publicly available information

Mariam Khanfar

New York University, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Acta Biochimica Polonica
Verified
Journal Article
Open access
PDF file
MAMahmoud Alfaqih
Mahmoud Alfaqih
ZAZaina E. Abu-Khdair
Zaina E. Abu-Khdair
OKOmar Khabour
Omar Khabour
Khalid A. KheirallahKhalid A. Kheirallah
Khalid A. Kheirallah
MKMariam Khanfar
Mariam Khanfar
The level of circulatory branched chain amino acids (BCAAs) is often increased in type 2 diabetes mellitus (T2DM). Catabolism of BCAAs involves a transamination reaction mediated by the branched chain amino acid aminotransferase (BCAT1) enzyme. Differences in the level of BCAT1 were found to be linked with hypertension, obesity, and cancer. Herein, using a case control design, we tested the association of rs9668920 and rs12321766 polymorphisms in BCAT1 gene with T2DM. Three hundred subjects were recruited in the study. Genotyping of the indicated polymorphisms was achieved using restriction fragment length polymorphism technique after amplification of the target sequences. The results showed that, under a recessive inheritance model, the GG genotype of rs9668920 increased the risk of T2DM (P=0.026; OR 2.60; 95% CI 1.119–6.048). This effect was independent of the age, body mass index, waist circumference, serum glucose, cholesterol, triglycerides, and BCAAs (P>0.05). In conclusion, The GG genotype of BCAT1 rs9668920 SNP might be a risk factor of T2DM. More studies are required to confirm this finding.

15 September 2025 in bioRxiv
Verified
Preprint
Open access
CRCaralyn Reisle
Caralyn Reisle
CGCameron J. Grisdale
Cameron J. Grisdale
KKKilannin Krysiak
Kilannin Krysiak
ADArpad M. Danos
Arpad M. Danos
MKMariam Khanfar
Mariam Khanfar
SJSteven Jones
Steven Jones
Accurate interpretation of genomic variants is critical for precision oncology but remains slow and dependent on specialized expertise. Public knowledgebases such as the Clinical Interpretation of Variants in Cancer (CIViC) help by curating literature-backed variant interpretations in a structured form, yet verification and review have become major bottlenecks. To address this, we developed CIViC-Fact, a benchmark dataset and pipeline for testing automated systems that verify the accuracy of cancer variant claims. CIViC-Fact links structured claims to sentence-level supporting or refuting evidence from full-text articles, and includes expert annotations and explanations. We evaluated multiple language models. Proprietary models performed well without training, but a smaller open-source model, fine-tuned on CIViC-Fact, achieved the highest accuracy (89%). Applying our fact-checking pipeline to real CIViC entries showed that reviewing less than 20% of content, focusing on flagged entries, would be sufficient to catch over half of all errors. This AI-assisted triage greatly accelerates the review process without replacing or reducing expert insight, ensuring that existing careful oversight remains in place while curators can work more efficiently. CIViC-Fact provides a realistic, high-consequence framework for biomedical fact-checking and a path toward more rigorous and efficient knowledgebase curation.

1 December 2020 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
EAEyad Altamimi
Eyad Altamimi
MKMariam Khanfar
Mariam Khanfar
OROMAR RABAB'H
OMAR RABAB'H
ZDZain Dardas
Zain Dardas
LSLuma Srour
Luma Srour
BABilal Azab
Bilal Azab
Purpose: Four consanguineous Jordanian families with affected members of unknown gastrointestinal related diseases were recruited to assess the utility and efficiency of whole exome sequencing (WES) in reaching the definitive diagnosis. Patients and Methods: Members from four consanguineous Jordanian families were recruited in this study. Laboratory and imaging tests were used for initial diagnosis, followed by performing WES to test all affected members for the detection of causative variants. Sanger sequencing was used for validation. Results: We had a 100% success rate identifying each case presented in this study. Conclusion: This is the first study applying a WES testing approach in the diagnosis of pediatric diseases in Jordan. Our results strongly suggest the need to implement WES as an evident diagnostic tool in the clinical setting, as it will subsequently allow for proper disease management and genetic counseling.

10 July 2021 in Congenital Anomalies
Verified
Journal Article
Closed access
PDF file
MAMontaha Al-Iede
Montaha Al-Iede
MKMariam Khanfar
Mariam Khanfar
LSLuma Srour
Luma Srour
RRRaja Rabah
Raja Rabah
MAMousa Al-Abbadi
Mousa Al-Abbadi
EBEman F Badran
Eman F Badran

1 July 2026 in medRxiv
Verified
Preprint
Open access
JYJennie X. Yao
Jennie X. Yao
KSKartik Singhal
Kartik Singhal
SKSusanna Kiwala
Susanna Kiwala
ESEvelyn Schmidt
Evelyn Schmidt
PGPeter Goedegebuure
Peter Goedegebuure
OGObi L. Griffith
Obi L. Griffith
Advancements in immunogenomics and immuno-oncology have enabled the development of personalized cancer vaccines (PCVs) that target cancer cell-specific somatic variants. A subset of these variants produce neoantigens that, when presented on tumor cells by MHC molecules, have the potential to elicit a robust and specific immune response. To date, there are over one hundred interventional studies listed on clinicaltrials.gov that explore the use of PCVs. We have supported a number of these trials through the creation of bioinformatic pipelines, tools, and procedures for the identification of patient-specific neoantigen candidates. While many of these steps have been automated, the final selection of neoantigen candidates often relies on expert manual review, creating a bottleneck that limits scalability and full automation of PCV workflows. Addressing this challenge, we introduce NEAT (Neoantigen Evaluation & Automated Triage), a machine learning-based approach that enables automated neoantigen candidate prioritization and supports the transition toward more scalable and reproducible PCV design. We implemented a prediction model trained and tested on existing vaccine design results from 33 patients and 1,943 peptides, across 3 clinical trials, including 439 peptides prioritized for PCV inclusion. This model uses features such as tumor variant allele frequency, RNA expression, driver gene status, binding/presentation scores, and transcript support level to automatically predict whether a peptide will be accepted, rejected, or require further human review before inclusion in a vaccine. The model achieved a sensitivity of 0.847 and specificity of 0.924, with an area under the curve of 0.955. The model predictions have been incorporated in pVACtools v7.0.0. By integrating this model into the vaccine development pipeline, we foresee a significant reduction in the time required to transition from patient sample collection to vaccine manufacturing, thereby enhancing the efficiency and scalability of PCV production.

5 October 2026 in Blood
Verified
Journal Article
Open access
HTHongwei Tang
Hongwei Tang
WPWilliam C Pilcher
William C Pilcher
HYHuihuang Yan
Huihuang Yan
ASAnnamalai Sivasankar
Annamalai Sivasankar
JDJinzhuang Dou
Jinzhuang Dou
LBLinda B Baughn
Linda B Baughn
The immune tumor microenvironment (iTME) plays a crucial role in disease biology of plasma cell (PC) dyscrasias, but remains poorly characterized in self-identified Black individuals, a population at increased risk. Mass cytometry and scRNA-seq of 128 bone marrow aspirates revealed significant changes in immune cell composition across the disease spectrum, including shifts from naïve to effector T cells with declines in B cells, MAIT, pDCs, and increases in monocytes with disease progression. Self-identified Black patients had higher relative proportions of terminally differentiated T cells and lower monocytes in newly diagnosed and treated multiple myeloma (MM). ScRNA-seq revealed genes overexpressed in self-identified Black individuals were enriched for E2F targets and G2-M checkpoints, while reduced genes were enriched for TNF-α/NF-kB, interferon and inflammatory responses pathways. These findings were supported by genetic ancestry and validated in an independent dataset of 286 patients with MM from the MMRF Immune Atlas. Self-identified race and African genetic similarity are significantly associated with remodeling the MM iTME, with potential implications for disease biology and treatment response.